Eli Lilly is slashing the self-pay prices of its 2.5 mg single-dose Zepbound vials to $349 per month and bringing its 5 mg single-dose vials down to $499 per month.
Fierce Pharma
Internet News
New York, New York 104,670 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
Only one of the world’s 22 top biopharma companies posted a year-over-year decline in the fourth quarter, reflecting an industry-wide revenue boom.
Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4
fiercepharma.com
-
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez less than a year after winning FDA approval.
Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
fiercepharma.com
-
Carlyle and SK Capital are taking what amounts to a $29 million gamble on a company that once was valued at more than $10 billion.
Once valued at $10B, bluebird bio sold to private equity firms for $29M
fiercepharma.com
-
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpart semaglutide in the U.S.
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
fiercepharma.com
-
The CDC's Advisory Committee on Immunization Practices postponed its scheduled Feb. 26-28 meeting, where it would have discussed newly approved vaccines from GSK and Bavarian Nordic.
A week after RFK Jr.'s confirmation, HHS postpones vaccine committee meeting
fiercepharma.com
-
The U.S.' top pharmaceutical trade group is drafting its ambitions for the next four years ahead of a planned meeting with the president.
PhRMA leaders prepare to meet with Trump as new chair Albert Bourla espouses optimism
fiercepharma.com
-
Bristol Myers Squibb’s Opdivo delivered an overall survival edge in a phase 3 study weighing the drug’s use as a preoperative treatment for non-small cell lung cancer.
Bristol Myers Squibb notches overall survival win with Opdivo in preoperative NSCLC
fiercepharma.com
-
The FDA signed off on Sanofi’s rapid-acting insulin Merilog, the first approved biosimilar to Novo Nordisk’s NovoLog.
FDA signs off on Sanofi's insulin biosimilar, the first for Novo Nordisk's rapid-acting NovoLog
fiercepharma.com
-
Ono Pharmaceutical’s Romvimza won an FDA green light to treat symptomatic tenosynovial giant cell tumor when surgery could potentially worsen a patient’s bodily function or cause severe illness.
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
fiercepharma.com